WAY · Waystar Holding Corp.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $272.13M | Six months ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net income 134.79M
+80.68M Interest expense, net
+60.29M Income tax expense
+156.66M Depreciation and amortization
+49.04M Stock-based compensation expense
+23.8M Acquisition and integration costs
+1.99M Asset and lease impairments
+2.81M Costs related to amended debt agreements
+1.47M IPO and Secondary Offering expenses
+2.45M Other
= Adjusted EBITDA 513.98M
|
|||
| Adjusted EBITDA margin non-GAAP | 43% | Six months ended June 30, 2026 | — |
|
|
|||
| Annual gross claims | $2.4T | annually | — |
| Clients | 30,000 | as stated in About Waystar | — |
| Clients contributed over $100,000 in LTM revenue | 1,453 | Q2 2026 | — |
|
|
|||
| Healthcare payment transactions | 7.5B | annually | — |
| Net revenue retention rate (NRR) | 108% | Q2 2026 | — |
| Non-GAAP net income non-GAAP | $164.45M | Six months ended June 30, 2026 | — |
| Non-GAAP net income per share, Basic non-GAAP | $0.86 | Six months ended June 30, 2026 | — |
| Non-GAAP net income per share, Diluted non-GAAP | $0.43 | Three months ended June 30, 2026 | — |
| Patient revenue | $87.9M | Q2 2026 | — |
| Provider revenue | $231.8M | Q2 2026 | — |
| Subscription revenue | $176.3M | Q2 2026 | +34.5% |
|
|
|||
| Trailing Twelve Months Adjusted EBITDA non-GAAP | 513.98M | TTM ended June 30, 2026 | — |
| Unlevered free cash flow non-GAAP | $63.9M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 59.41M
+20.61M Interest paid
-16.11M Purchase of PP&E and capitalization of internally developed software costs
= Unlevered free cash flow 63.91M
|
|||
| Volume-based revenue | $142.1M | Q2 2026 | +2.8% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WAY
this stock
Waystar Holding Corp.
|
$4.66B | -25.7% | +16.5% | 34.7 | 7.6% |
|
VEEV
Veeva Systems Inc
|
$39.43B | +8.7% | +28.1% | 43.0 | 4.5% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$13.02B | -24.9% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.77B | +58.4% | +28.2% | 36.1 | 4.2% |
|
TEM
Tempus AI, Inc.
|
$8.91B | -16.4% | +83.4% | — | 18.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WAY | +0.1% | +13.1% | -0.3% | +15.2% | -25.7% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +0.5% | +10.5% | -11.1% | +12.5% | -38.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.